Ontology highlight
ABSTRACT: Background
Epidermal growth factor receptor (EGFR) mutation detection is essential for the therapy of lung cancer. A sensitive, specific, and cost-effective standardized method to quickly and accurately detect EGFR mutations is urgently needed.Methods
We evaluated the Idylla™ EGFR Mutation Assay for EGFR mutations in formalin-fixed, paraffin-embedded (FFPE) tumor samples from 232 lung cancer patients, and compared the results with amplification refractory mutation system (ARMS) (n=146) and next-generation sequencing (NGS) (n=86). The surgical tumor sections and cell blocks derived from the same FFPE section were compared. Overall concordance, specificity, sensitivity, cost-effectiveness and turnaround time were compared among the three methods.Results
The overall concordance between Idylla and ARMS was 89.51% [95% confidence interval (CI): 83.31% to 93.64%] and the specificity of Idylla was 88.68% (95% CI: 80.69% to 93.76%). A concordance of 97.67% (95% CI: 91.41% to 99.86%) was obtained between Idylla and NGS, the specificity of Idylla was 96.30% (95% CI: 86.16% to 99.36%). Compared to the ARMS and NGS, the Idylla™ system significantly reduces the turnaround time. Combining labor, equipment, reagents and time costs, Idylla is more affordable.Conclusions
Clinically urgent cases with adequate cellularity, can first perform Idylla to detect critical markers, then perform NGS for a comprehensive mutation analysis. Besides, with limited molecular expertise or infrastructure, the Idylla has the potential to extend EGFR testing to more pathology laboratories in primary hospitals.
SUBMITTER: Xu Y
PROVIDER: S-EPMC10894364 | biostudies-literature | 2024 Jan
REPOSITORIES: biostudies-literature
Xu Yuyin Y Zhang Ling L Jia Liqing L Ren Min M Xue Tian T Bai Qianming Q Yao Qianlan Q Wei Ran R Zhou Xiaoyan X Zhu Xiaoli X
Journal of thoracic disease 20240108 1
<h4>Background</h4>Epidermal growth factor receptor (<i>EGFR</i>) mutation detection is essential for the therapy of lung cancer. A sensitive, specific, and cost-effective standardized method to quickly and accurately detect <i>EGFR</i> mutations is urgently needed.<h4>Methods</h4>We evaluated the Idylla™ EGFR Mutation Assay for <i>EGFR</i> mutations in formalin-fixed, paraffin-embedded (FFPE) tumor samples from 232 lung cancer patients, and compared the results with amplification refractory mut ...[more]